New test could predict falls in muscle disease patients
NCT ID NCT06605612
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study aims to create a simple test battery to determine fall risk in people with neuromuscular disorders, such as muscular dystrophy or ALS. Researchers will assess 108 participants using several physical tests like walking, standing, and rising from a chair. The goal is to provide clear guidelines for when to use walking aids like canes or walkers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a simple, standard way to assess fall risk and decide when a walking aid is needed for people with neuromuscular disorders.
- What could go wrong
- This is an early validation study with only 108 participants. The tests may not work for all types of neuromuscular disorders or may need further refinement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Friedrich-Baur-Institut, Neurologische Klinik und Poliklinik, LMU Klinikum, Ludwig-Maximilians-Universität München
München, Bavaria, 80336, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking daily life unlock myasthenia gravis mysteries?
- Can engineered immune cells tame a debilitating autoimmune disease?
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can a new antibody calm the immune attack in CIDP?
- Could a brain disease change behavior years before diagnosis?
- Can a cancer drug slow ALS? a trial aims to find out